A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease
| Image |  |
|---|---|
| Description | scholarly article by Michael Grundman et al published 2019 in Alzheimer's & dementia (New York, N. Y.) |
| Author/s |
author: Nicholas J. Izzo Lon S Schneider Steven T. DeKosky Michael Grundman |
| Publication date | 2019 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |